Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0012863,
umls-concept:C0033684,
umls-concept:C0040648,
umls-concept:C0392747,
umls-concept:C0439596,
umls-concept:C0439849,
umls-concept:C0439851,
umls-concept:C0441655,
umls-concept:C0445223,
umls-concept:C0871261,
umls-concept:C1552596,
umls-concept:C1552599,
umls-concept:C1554963,
umls-concept:C1704632,
umls-concept:C1704675,
umls-concept:C1704787,
umls-concept:C1706817,
umls-concept:C1947931,
umls-concept:C2911692
|
pubmed:issue |
3
|
pubmed:dateCreated |
1993-5-28
|
pubmed:abstractText |
DNA topoisomerase II (topo II) is an essential nuclear enzyme which catalyzes the interconversions of various forms of DNA. As predicted from the human topo II cDNA, the enzyme contains a potential leucine zipper protein dimerization motif. We therefore tested whether topo II could enter protein-protein interactions with other better characterized leucine zipper-containing proteins and determined if these interactions could modify topo II enzymatic activity in vitro. By far Western analyses, a large C-terminal fragment of human topo II was shown to interact with the DNA binding and dimerization regions of either cAMP response element binding protein (CREB) or the activating transcription factor-2. The C-terminal topo II fragment also interacted with full-length c-Jun, but not with full-length c-Fos. Using CREB as a prototype, the effect of this interaction on various topo II catalytic activities was assessed in vitro. CREB, at a 1- to 10-fold molar excess relative to topo II, inhibited site-specific DNA cleavage activity on a 242-base pair fragment of the human alpha-glycoprotein hormone subunit gene promoter. Very high CREB concentrations (400-fold excess) apparently inhibited topo II DNA relaxation activity, but this result was likely a direct effect of CREB on the topology of the DNA substrate. More interestingly, a 10-fold molar excess of CREB stimulated topo II decatenation activity, the essential function of this enzyme in cell division. This stimulatory effect could also be elicited by c-Jun, which interacts with topo II, but not by c-Fos, which does not bind topo II in our in vitro assay. Since similar amounts of CREB reduced the abundance of topo II DNA cleavage products from the human alpha-CG promoter yet also stimulated decatenation activity, it can be concluded that either: 1) CREB stimulated the religation rate of topo II; or 2) CREB directed topo II to a new cleavage site present on the decatenation substrate but not present on the limited alpha-CG promoter. The structural requirements for topo II protein-protein interactions were also investigated. Site-directed mutations which destroyed the putative topo II leucine zipper did not disrupt topo II protein-protein interactions. Since the putative leucine zipper in topo II does not appear to mediate protein-protein interactions, we propose that an alternate as yet uncharacterized structure is involved in the association of topo II with itself and other regulatory proteins.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP Response...,
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Superhelical,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-fos,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-jun,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0888-8809
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
305-18
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8387155-Amino Acid Sequence,
pubmed-meshheading:8387155-Base Sequence,
pubmed-meshheading:8387155-Blotting, Western,
pubmed-meshheading:8387155-Cyclic AMP Response Element-Binding Protein,
pubmed-meshheading:8387155-DNA,
pubmed-meshheading:8387155-DNA, Superhelical,
pubmed-meshheading:8387155-DNA Topoisomerases, Type II,
pubmed-meshheading:8387155-Electrophoresis, Polyacrylamide Gel,
pubmed-meshheading:8387155-Escherichia coli,
pubmed-meshheading:8387155-Gene Expression Regulation,
pubmed-meshheading:8387155-Leucine Zippers,
pubmed-meshheading:8387155-Molecular Sequence Data,
pubmed-meshheading:8387155-Mutagenesis, Site-Directed,
pubmed-meshheading:8387155-Plasmids,
pubmed-meshheading:8387155-Proto-Oncogene Proteins c-fos,
pubmed-meshheading:8387155-Proto-Oncogene Proteins c-jun,
pubmed-meshheading:8387155-Time Factors,
pubmed-meshheading:8387155-Transcription, Genetic,
pubmed-meshheading:8387155-Transcription Factors
|
pubmed:year |
1993
|
pubmed:articleTitle |
Modification of DNA topoisomerase II activity via direct interactions with the cyclic adenosine-3',5'-monophosphate response element-binding protein and related transcription factors.
|
pubmed:affiliation |
Division of Medical Oncology, University of Colorado Health Sciences Center, Denver 80262.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|